|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
178.65(B) |
Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
52
Week Range: |
$217.36 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
Total People Sold |
1 |
1 |
3 |
6 |
Total Sell Transactions |
1 |
1 |
4 |
8 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Patton Cynthia M |
SVP & CCO |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
984 |
24,560 |
|
- |
|
Hooper Anthony C |
EVP, Global Commercial Ops. |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,920 |
203,402 |
|
- |
|
Johnston Lori A |
SVP, HR |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,968 |
15,322 |
|
- |
|
Mcnamee Brian M |
EVP |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,444 |
102,516 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,760 |
396,242 |
|
- |
|
Harper Sean E |
EVP, Research & Development |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,551 |
60,496 |
|
- |
|
Graham Jonathan P |
SVP, Gen. Counsel & Secy. |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
50,619 |
|
- |
|
Sugar Ronald D |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
11,286 |
|
- |
|
Williams R Sanders |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
4,009 |
|
- |
|
Pelham Judith C |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
11,232 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
1,640 |
|
- |
|
Jacks Tyler |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
7,598 |
|
- |
|
Holley Charles M |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
1,230 |
|
- |
|
Herringer Frank C |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
32,011 |
|
- |
|
Hassan Fred |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
6,091 |
|
- |
|
Henderson Rebecca M |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
11,665 |
|
- |
|
De Carbonnel Francois |
Director |
|
2017-05-01 |
4 |
D |
$163.32 |
$56,019 |
D/D |
(343) |
19,498 |
|
- |
|
De Carbonnel Francois |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
19,841 |
|
- |
|
Eckert Robert |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
8,150 |
|
- |
|
Garland Greg C. |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
5,924 |
|
- |
|
Biondi Frank |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
36,635 |
|
- |
|
Baltimore David |
Director |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,230 |
34,859 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2017-04-26 |
4 |
D |
$164.70 |
$31,458 |
D/D |
(191) |
14,616 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2017-04-26 |
4 |
D |
$164.70 |
$458,360 |
D/D |
(2,783) |
32,549 |
|
- |
|
Such Annette Louise |
VP, Finance and CAO |
|
2017-04-26 |
4 |
D |
$164.70 |
$7,247 |
D/D |
(44) |
7,863 |
|
- |
|
2206 Records found
|
|
Page 27 of 89 |
|
|